View this as a webpage

Minnesota Department of Health

February 11, 2022

Update on Pfizer’s COVID-19 vaccine for people under 5 years

The Food and Drug Administration (FDA) Vaccine and Related Biologics Advisory Committee (VRBPAC) has postponed their Feb. 15 meeting where they were prepared to discuss Pfizer’s COVID-19 vaccine for children 6 months through 4 years. The VRBPAC meeting will be scheduled once there is additional data on a third dose in this age group and sufficient time to review the data. For more information refer to the FDA’s press announcement: Coronavirus (COVID-19) Update: FDA Postpones Advisory Committee Meeting to Discuss Request for Authorization of Pfizer-BioNTech COVID-19 Vaccine for Children 6 Months Through 4 Years of Age.

For those who placed orders for this vaccine this week, your order will not be processed and vaccine will not be shipped to you at this time.

ACIP recommends Moderna’s Spikevax (COVID-19 vaccine)

On Feb. 4, the Advisory Committee on Immunization Practices (ACIP) voted to recommend the FDA-approved Moderna’s Spikevax (COVID-19 vaccine) in people 18 years and older when administered as a primary series of two doses. Moderna’s COVID-19 mRNA vaccine continues to be available under emergency use authorization (EUA) as an additional dose for immunocompromised people and a booster dose. Spikevax and the Moderna COVID-19 vaccine have the same formulation and can be used interchangeably.

Read more in news releases at FDA: Coronavirus (COVID-19) Update: FDA Takes Key Action by Approving Second COVID-19 Vaccine and CDC Statement Following ACIP Moderna Vote.

Find previous bulletins at COVID-19 Vaccine Provider Updates.

Manage Preferences  |  Unsubscribe  |  Help  |  health.state.mn.us